



Scientific Session

The Myasthenia Gravis Foundation of America (MGFA) Medical/Scientific Advisory Council presents a scientific session highlighting research in MG and myasthenic disorders. This session is the one of the premier annual events around the U.S. and world related to the pathogenesis, immunology, diagnosis, and treatment of MG and related disorders of the NMJ. Included in the program will be leaders in MG research from the scientific and clinical areas.

The MGFA Scientific Session Steering Committee is:

Shruti Raja, MD, Chair - Duke Health

Ali Habib, MD, University of California, Irvine

Diana Castro, MD, Founder of Neurology and Neuromuscular Care Center, Founder of Neurology Rare Disease Center

MGFA's Scientific Session Agenda

8:00 am: Welcome - Samantha Masterson, CEO, President, MGFA

8:05 am: Introduction Keynote - Shruti Raja, MD

8:10 am: Keynote: Development and Validation of MG-Specific Outcome Measures - Carolina Barnett-Tapia, MD, PhD

8:50 am: Introduction – Clinical Trials 1 - Ali Habib, MD

8:52 am: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Subcutaneous Batoclimab in Patients with Generalized Myasthenia Gravis - Richard Nowak, MD, MS

8:57 am: Real World Assessment and Patient Perceptions of a Prototype Myasthenia Gravis Symptom-Tracking Application
- Omar Sinno, MD, MBA

9:02 am: A Pharmacodynamic Noninferiority Study Comparing Subcutaneous Injections of Efgartigimod Ph20 with Intravenous Infusions of Efgartigimod: Results of the Phase 3 ADAPTSC Study
- James Howard, MD

9:07 am: Disparities in North American Myasthenia Gravis Clinical Trial Participation - Jose Sanchez, MD

9:17 am: Introduction – Basic Science - Diana Castro, MD

9:19 am: MuSK-CAART: a novel precision cellular immunotherapy for MuSK myasthenia gravis
- Aimee Payne, MD, PhD (Nancy Law High Impact Award Winner)

9:34 am: CD8 T Cell Immune Signatures in Autoimmune Myasthenia Gravis - Kevin Li, PhD

9:39 am: Characterization of CD11C⁺ B Cells In ACHR AB⁺ Myasthenia Gravis - Patricia Sikorski, PhD

9:44 am: Phase 1/2A Study Of Descartes-08, Autologous MRNA-Engineered Chimeric Antigen Receptor T Cells, in Generalized Myasthenia Gravis - Volkan Granit, MD

10:05 am: Break – Visit the Exhibits and Posters

10:35 am: Introduction – Clinical Trials 2 - Shruti Raja, MD

10:37 am: Ravulizumab for the Treatment of Generalized Myasthenia Gravis: Timing of Response - Ali Habib, MD

10:52 am: Quality of Life Outcomes In Raise: A Double-Blind Randomized, Placebo-Controlled Study of Zilucoplan in GMG - Michael Weiss, MD

10:57 am: Efficacy of Efgartigimod Treatment in Patients with Anti-Acetylcholine Receptor Antibody Negative Myasthenia Gravis: Clinical Trial and Real-World Data - Tania Papsdorf, MD

11:02 am: Safety and Tolerability of Rozanolixizumab in the Randomized Phase 3 MyCaring Study - Tuan Vu, MD

11:13 am: Introduction – Outcomes - Diana Castro, MD

11:15 am: A Phase 3, Open-Label, Multicenter Study to Evaluate Eculizumab in Adolescents with Refractory Generalized Myasthenia Gravis - John Brandsema, MD

11:30 am: Outcomes of Covid-19 Infection and Vaccination in Individuals with Myasthenia Gravis: A Population-Based Study - Monica Alcantara, MD, PhD

11:35 am: A Phase 3b Open-Label Study to Further Individualize Efgartigimod Treatment Options for Patients with Generalized Myasthenia Gravis - Kelly Gwathmey, MD

11:40 am: Risk Benefit Analysis of Treatments for Patients with Myasthenia - A Gordon Smith, MD, FAAN

Program and speakers subject to change.

We Thank Our Generous Industry Partners and Sponsors. We Appreciate Your Commitment to the Myasthenia Population.

NATIONAL PRESENTING PARTNERS



NATIONAL SPONSORS



for more information, visit myasthenia.org
contact us at mgfa@myasthenia.org

Connect with us:



[/MyastheniaGravisFoundation](https://www.facebook.com/MyastheniaGravisFoundation)



[/myastheniaorg](https://www.instagram.com/myastheniaorg)



[/myastheniaorg](https://twitter.com/myastheniaorg)